# GENERAL ATLANTIC, L.P.

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1017645. Source: https://holderbook.com/funds/1017645-general-atlantic-l-p/

- Reported value: $2.9B
- Positions: 12
- Weight of the ten largest: 99.0%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| LIFTOFF MOBILE INC | [LFTO](https://holderbook.com/stocks/LFTO/) | $608.1M | 25,315,646 | 20.9% | 1 |
| DLOCAL LTD | [DLO](https://holderbook.com/stocks/DLO/) | $606.3M | 46,656,695 | 20.9% | 21 |
| CHIME FINL INC | [CHYM](https://holderbook.com/stocks/CHYM/) | $435.4M | 21,259,683 | 15.0% | 5 |
| ALKAMI TECHNOLOGY INC | [ALKT](https://holderbook.com/stocks/ALKT/) | $351.1M | 19,379,038 | 12.1% | 21 |
| XP INC | [XP](https://holderbook.com/stocks/XP/) | $334.4M | 20,566,133 | 11.5% | 27 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $226.5M | 6,550,757 | 7.8% | 22 |
| SEAPORT THERAPEUTICS INC | [SPTX](https://holderbook.com/stocks/SPTX/) | $132.5M | 6,101,582 | 4.6% | 1 |
| NURIX THERAPEUTICS INC | [NRIX](https://holderbook.com/stocks/NRIX/) | $73.6M | 3,032,185 | 2.5% | 3 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $67.0M | 357,791 | 2.3% | 4 |
| PARABILIS MEDICINES INC | [PBLS](https://holderbook.com/stocks/PBLS/) | $42.1M | 1,538,461 | 1.4% | 1 |
| RISKIFIED LTD | [RSKD](https://holderbook.com/stocks/RSKD/) | $26.8M | 5,324,998 | 0.9% | 20 |
| GROVE COLLABORATIVE HOLD INC | [GROV](https://holderbook.com/stocks/GROV/) | $3.1M | 2,474,859 | 0.1% | 13 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +8.7% | +14.8% | -6.1% | 94% |
| Q1 2026 | -3.4% | -4.6% | +1.2% | 100% |
| Q4 2025 | +4.3% | +2.4% | +1.9% | 92% |
| Q3 2025 | +2.9% | +7.8% | -4.9% | 100% |
| Q2 2025 | +8.2% | +10.5% | -2.3% | 100% |
| Q1 2025 | +6.5% | -4.6% | +11.0% | 100% |
| Q4 2024 | +2.2% | +2.1% | +0.1% | 86% |
| Q3 2024 | +12.7% | +5.4% | +7.2% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $2.9B | 12 |
| Q1 2026 | $2.1B | 12 |
| Q4 2025 | $2.9B | 13 |
| Q3 2025 | $3.3B | 16 |
| Q2 2025 | $3.6B | 15 |
| Q1 2025 | $3.0B | 15 |
| Q4 2024 | $2.8B | 16 |
| Q3 2024 | $3.5B | 18 |
| Q2 2024 | $3.2B | 19 |
| Q1 2024 | $4.3B | 22 |
| Q4 2023 | $7.0B | 26 |
| Q3 2023 | $6.5B | 29 |